- Prevention of acute and delayed nausea and vomiting associated with highly and moderately emetogenic chemotherapy:
- Adults: IV 150mg on Day 1 of chemotherapy, 30 minutes before the start of chemotherapy
Injection:
- 150mg
- Administer intravenously over 20 to 30 minutes.
- It should be given in combination with other antiemetic agents such as a corticosteroid (e.g., dexamethasone) and a 5-HT3 antagonist (e.g., ondansetron).
NK1 Receptor Antagonist. It is a prodrug of aprepitant
It inhibits the NK1 receptors in the brain, which are involved in the vomiting reflex. It is rapidly converted to aprepitant after administration, providing prolonged antiemetic effects.
- Headache
- Hiccups
- Tiredness
- Loss of appetite
- Indigestion
- Constipation
- Hypersensitivity to fosaprepitant, aprepitant or any of the components of the formulation.
- Hepatic problems
- Pimozide
- Astemizole
- Terfenadine
- Cisapride
- Tacrolimus
- Everolimus
- Cyclosporine
- Sirolimus
- Fentanyl
- Alfentanil
- Quinidine
- Etoposide
- Irinotecan
- Ifosfamide
- Acenocoumarol
- Warfarin
- Clarithromycin
- Telithromycin
- Rifampicin
- Phenytoin
- Carbamazepine
- Triazolam
- Phenobarbital
- Midazolam
- Ketoconazole
- Voriconazole
- Posaconazole
- Itraconazole
- Nefazodone
- Diltiazem
- Dexamethasone
- Alprazolam
- Tolbutamide
- Oral contraceptives
Drug Status
| Availability | Prescription only |
| Pregnancy | Weigh risk vs benefit |
| Breastfeeding | Not recommended |
| Schedule | Not controlled |
| BRAND NAME | STRENGTH | FORMULATION | PACK SIZE | MANUFACTURER | DISTRIBUTOR |
|---|---|---|---|---|---|
| Apritant | 150mg | Injection | 1’s | MSN Labs | MSN Labs |